Jody Tversky, MD
Allergy · Baltimore, MDNPI 1619014263
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $149,775 of the $175,257 with a category attached, or 85.5%. AstraZeneca accounts for 87.9% of it on its own, with 6 other manufacturers making up the rest. Among allergy clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $803.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$154K
- Amgen$21K
- Sanofi$127
- ADMA Biomanufacturing LLC$109
- Grifols USA, LLC$99
- Bayer$36
- plus $12 from 1 others
Across 78 payments — averaging $28,620 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1.7M
- AstraZeneca$492K
- Bristol Myers Squibb$11K
- Sanofi$750
What the payments were for
- Consulting fees$5,9223%
- Speaking & faculty fees$149,77585%
- Travel & lodging$14,3798%
- Food & beverage$5,1813%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 191 | $153,976 |
| Amgen | 21 | $20,897 |
| Sanofi | 1 | $127 |
| ADMA Biomanufacturing LLC | 1 | $109 |
| Grifols USA, LLC | 1 | $99 |
| Bayer | 2 | $36 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$175,257 in reported general payments places this provider in the 90th percentile of 29 allergy providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 21 | $79,187 |
| XolairOmalizumab | 14 | $36,973 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $261 |
Paid to pharmacies, not to this prescriber.
Other allergy in Baltimore
- David GoldenBaltimore$197K
- Sarbjit SainiBaltimore$174K
- Newton AdkinsonBaltimore$61K
- Peter CreticosBaltimore$22K
- Gitika DhillonBaltimore$8K
- Alkis TogiasBaltimore$67
- Huamin LiWheaton$576K
- Jonathan MatzWhite Marsh$147K
- Brett CoonsJb Andrews$49K
- David SchwartzBethesda$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.